Neutrophil oxidative burst activates ATM to regulate cytokine production and apoptosis

Blood

Volumn 126, Issue 26, 2015, Pages 2842-2851

  Harbort, C J ^a   Soeiro Pereira, Paulo Vitor ^b   Von Bernuth, Horst ^c   Kaindl, Angela M ^c   Costa Carvalho, Beatriz Tavares ^d   Condino Neto, Antonio ^e   Reichenbach, Janine ^f,g   Roesler, Joachim ^h   Zychlinsky, Arturo ^a   Amulic, Borko ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f Children's Research Centre   (United States)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA; ATM PROTEIN, HUMAN;

ADOLESCENT; APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; CATALYSIS; CELL VIABILITY; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIFESPAN; NEUTROPHIL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY BURST; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL SEPARATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BLOTTING, WESTERN; CELL SEPARATION; CYTOKINES; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; NEUTROPHILS; REAL-TIME POLYMERASE CHAIN REACTION; RESPIRATORY BURST;

EID: 84954472661     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-645424     Document Type: Article

References (52)

1. Lavin MF, Shiloh Y. The genetic defect in ataxiatelangiectasia. Annu Rev Immunol. 1997;15:177-202.
2. Levis WR, Dattner AM, Shaw JS. Selective defects in T cell function in ataxia-telangiectasia. Clin Exp Immunol. 1979;37(1):44-49.
3. Paganelli R, Scala E, Scarselli E, et al. Selective deficiency of CD41/CD45RA1 lymphocytes in patients with ataxia-telangiectasia. J Clin Immunol. 1992;12(2):84-91.
4. Schubert R, Reichenbach J, Zielen S. Deficiencies in CD41 and CD81 T cell subsets in ataxia telangiectasia. Clin Exp Immunol. 2002; 129(1):125-132.
5. Schubert R, Reichenbach J, Royer N, Pichler M, Zielen S. Spontaneous and oxidative stressinduced programmed cell death in lymphocytes from patients with ataxia telangiectasia (AT). Clin Exp Immunol. 2000;119(1):140-147.
6. Chopra C, Davies G, Taylor M, et al. Immune deficiency in Ataxia-Telangiectasia: a longitudinal study of 44 patients. Clin Exp Immunol. 2014; 176(2):275-282.
7. Sanal O, Ersoy F, Yel L, et al. Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxiatelangiectasia. J Clin Immunol. 1999;19(5): 326-334.
8. Bott L, Lebreton J, Thumerelle C, Cuvellier J, Deschildre A, Sardet A. Lung disease in ataxiatelangiectasia. Acta Paediatr. 2007;96(7): 1021-1024.
9. Schroeder SA, Swift M, Sandoval C, Langston C. Interstitial lung disease in patients with ataxiatelangiectasia. Pediatr Pulmonol. 2005;39(6): 537-543.
10. Ammann AJ, Hong R. Autoimmune phenomena in ataxia telangiectasia. J Pediatr. 1971;78(5): 821-826.
11. Reichenbach J, Schubert R, Schindler D, Müller K, Böhles H, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal. 2002;4(3):465-469.
12. McGrath-Morrow SA, Collaco JM, Crawford TO, et al. Elevated serum IL-8 levels in ataxia telangiectasia. J Pediatr. 2010;156(4):682-684.
13. McKinnon PJ. ATM and ataxia telangiectasia. EMBO Rep. 2004;5(8):772-776.
14. Privette ED, Ram G, Treat JR, Yan AC, Heimall JR. Healing of granulomatous skin changes in ataxia-telangiectasia after treatment with intravenous immunoglobulin and topical mometasone 0.1% ointment. Pediatr Dermatol. 2014;31(6):703-707.
15. Drolet BA, Drolet B, Zvulunov A, Jacobsen R, Troy J, Esterly NB. Cutaneous granulomas as a presenting sign in ataxia-telangiectasia. Dermatology. 1997;194(3):273-275.
16. Chiam LY, Verhagen MM, Haraldsson A, et al. Cutaneous granulomas in ataxia telangiectasia and other primary immunodeficiencies: reflection of inappropriate immune regulation? Dermatology. 2011;223(1):13-19.
17. Mitra A, Gooi J, Darling J, Newton-Bishop JA. Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia. J Am Acad Dermatol. 2011;65(3): 676-677.
18. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000; 1(3):179-186.
19. Smith J, Tho LM, Xu N, Gillespie DA. The ATMChk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108: 73-112.
20. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013; 14(4):197-210.
21. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science. 2010;330(6003):517-521.
22. Barzilai A, Rotman G, Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst). 2002;1(1):3-25.
23. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. 2012;30:459-489.
24. Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nat Rev Immunol. 2013; 13(5):349-361.
25. El Kebir D, Filep JG. Role of neutrophil apoptosis in the resolution of inflammation. Scientific World Journal. 2010;10:1731-1748.
26. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22(3):285-294.
27. Lekstrom-Himes JA, Kuhns DB, Alvord WG, Gallin JI. Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J Immunol. 2005;174(1):411-417.
28. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176(2):231-241.
29. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood. 2003;102(7):2660-2669.
30. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004;64(24): 9152-9159.
31. Luo HR, Loison F. Constitutive neutrophil apoptosis: mechanisms and regulation. Am J Hematol. 2008;83(4):288-295.
32. Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). J Clin Immunol. 2008;28(Suppl 1):S67-S72.
33. Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ. Diminished production of antiinflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol. 2003;73(5):591-599.
34. Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol. 2012; 2012:252460.
35. Kim J, Wong PK. Loss of ATM impairs proliferation of neural stem cells through oxidative stress-mediated p38 MAPK signaling. Stem Cells. 2009;27(8):1987-1998.
36. Bensimon A, Aebersold R, Shiloh Y. Beyond ATM: the protein kinase landscape of the DNA damage response. FEBS Lett. 2011;585(11): 1625-1639.
37. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005;15(1): 11-18.
38. Wang Q, Franks HA, Lax SJ, et al. The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells. J Immunol. 2013;190(7):3246-3255.
39. Figueiredo N, Chora A, Raquel H, et al. Anthracyclines induce DNA damage responsemediated protection against severe sepsis. Immunity. 2013;39(5):874-884.
40. Härtlova A, Erttmann SF, Raffi FA, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote antimicrobial innate immunity. Immunity. 2015;42(2): 332-343.
41. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001;15(17):2177-2196.
42. Pommier Y, Sordet O, Rao VA, Zhang H, Kohn KW. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des. 2005;11(22):2855-2872.
43. Dai B, Zhao XF, Mazan-Mamczarz K, et al. Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nat Commun. 2011;2:402.
44. Wang XQ, Redpath JL, Fan ST, Stanbridge EJ. ATR dependent activation of Chk2. J Cell Physiol. 2006;208(3):613-619.
45. Xu Y, Loison F, Luo HR. Neutrophil spontaneous death is mediated by down-regulation of autocrine signaling through GPCR, PI3Kgamma, ROS, and actin. Proc Natl Acad Sci USA. 2010;107(7): 2950-2955.
46. Kaufman DB, Miller HC. A taxia telangiectasia: an autoimmune disease associated with a cytotoxic antibody to brain and thymus. Clin Immunol Immunopathol. 1977;7(2):288-299.
47. Ammann AJ, Hong R. Ataxia-telangiectasia and autoimmunity. Pediatr Res. 1970;4(5):435.
48. Martin-Villa JM, Corell A, Ramos-Amador JT, Ruiz-Contreras J, Arnaiz-Villena A. Higher incidence of autoantibodies in X-linked chronic granulomatous disease carriers: random X-chromosome inactivation may be related to autoimmunity. Autoimmunity. 1999;31(4): 261-264.
49. De Ravin SS, Naumann N, Cowen EW, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol. 2008;122(6):1097-1103.
50. Westbrook AM, Schiestl RH. Atm-deficient mice exhibit increased sensitivity to dextran sulfate sodium-induced colitis characterized by elevated DNA damage and persistent immune activation. Cancer Res. 2010;70(5):1875-1884.
51. Eickmeier O, Kim SY, Herrmann E, et al. Altered mucosal immune response after acute lung injury in a murine model of Ataxia Telangiectasia. BMC Pulm Med. 2014;14:93.
52. Chessa L, Leuzzi V, Plebani A, et al. Intraerythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis. 2014;9:5.